Dr Kendle Maslowski
Microbial and Metabolic Immune Modulation
Our lab is interested in the interplay between microbes, epithelium and the immune system in the intestine. Bacteria have been used experimentally as cancer therapeutic agents since the work of William Coley in the early 1900’s, yet only one bacterial cancer therapy (BCT) is in clinical use; BCG therapy for superficial bladder cancer. We are working toward understanding and improving BCTs by investigating mechanisms of bacterial adaptation to the tumour, direct effects of bacteria on tumour growth and effects on immune responses. More broadly, we are interested in host-microbe interplay within the intestine as can be soon in a word cloud generated from our publications (Figure 1).
Biography
click here to read
Recent Publications
click here to read
Biography
My name is Kendle. I have a long-standing interest in host—microbe interactions, especially those driven by metabolites. I am originally from Australia, where I did my PhD at the Garvan Institute. I postdoc-ed at the University of Lausanne, Switzerland and the RIKEN Institute for Medical Science, Japan before starting my lab at the University of Birmingham in 2017. I since relocated to the CRUK SI where we are building on our knowledge and application of bacterial cancer therapies. Excited about all thing’s buggy. Outside of work I love gardening, hiking, baking and hanging out with my son.
Education and qualifications
- 2011: PhD, University of New South Wales, Sydney, Australia; Supervisor: Prof Charles Mackay, Project: The role of GPR43 in the immune system: a novel connection between diet, gut microbiota and immune function
- 2006: BSc with Honours, Molecular Biology, Murdoch University, Perth, Australia
- 2005: BSc, Molecular Biology, Murdoch University, Perth, Australia
Appointments
- 2023–present: Beatson Research Fellow, CRUK Career Development Fellow, CRUK Scotland Institute, Glasgow, UK
- 2022–2023: Associate Professor and CRUK Career Establishment Fellow, Institute of Immunology and Immunotherapy, University of Birmingham, UK
- 2017–2022: Birmingham Fellow and CRUK Career Establishment Fellow, Institute of Immunology and Immunotherapy, University of Birmingham, UK
- 2014–2017: Postdoctoral Researcher with Prof Hiroshi Ohno, RIKEN, Centre for Integrative Medical Sciences, Yokohama, Japan
- 2011–2014: Postdoctoral Researcher with Prof Jürg Tschopp, Department of Biochemistry, University of Lausanne, Switzerland
- 2007–2007: Research Assistant with Prof Charles Mackay, Garvan Institute of Medical Research, Sydney, Australia
Funding
- Beatson Cancer Charity
Recent Publications
2024
Copland A, Mackie GM, Scarfe L, Jinks E, Lecky DAJ, Gudgeon N, McQuade R, Ono M, Barthel M, Hardt W-D, Ohno H, Hoevenaar WHM, Dimeloe S, Bending D, Maslowski KM. Salmonella cancer therapy metabolically disrupts tumours at the collateral cost of T cell immunity. EMBO Molecular Medicine. 0(0):1-32.
2023
Fisch D, Pfleiderer MM, Anastasakou E, Mackie GM, Wendt F, Liu X, Clough B, Lara-Reyna S, Encheva V, Snijders AP, Bando H, Yamamoto M, Beggs AD, Mercer J, Shenoy AR, Wollscheid B, Maslowski KM, Galej WP, Frickel EM. PIM1 controls GBP1 activity to limit self-damage and to guard against pathogen infection. Science. 2023;382(6666):eadg2253.
2022
Bishop EL, Gudgeon NH, Mackie GM, Chauss D, Roberts J, Tennant DA, Maslowski KM, Afzali B, Hewison M, Dimeloe S. 1,25-Dihydroxyvitamin D3 suppresses CD4(+) T-cell effector functionality by inhibition of glycolysis. Immunology. 2022;166:299-309.
Bombaci G, Sarangdhar MA, Andina N, Tardivel A, Yu EC, Mackie GM, Pugh M, Ozan VB, Banz Y, Spinetti T, Hirzel C, Youd E, Schefold JC, Taylor G, Gazdhar A, Bonadies N, Angelillo-Scherrer A, Schneider P, Maslowski KM, Allam R. LRR-protein RNH1 dampens the inflammasome activation and is associated with COVID-19 severity. Life Sci Alliance. 2022;5.
Elliot TAE, Jennings EK, Lecky DAJ, Rouvray S, Mackie GM, Scarfe L, Sheriff L, Ono M, Maslowski KM, Bending D. Nur77-Tempo mice reveal T cell steady state antigen recognition. Discov Immunol. 2022;1:kyac009.
2021
Elliot TAE, Jennings EK, Lecky DAJ, Thawait N, Flores-Langarica A, Copland A, Maslowski KM, Wraith DC, Bending D. Antigen and checkpoint receptor engagement recalibrates T cell receptor signal strength. Immunity. 2021;54:2481-2496.e2486.
Mackie GM, Copland A, Takahashi M, Nakanishi Y, Everard I, Kato T, Oda H, Kanaya T, Ohno H, Maslowski KM. Bacterial cancer therapy in autochthonous colorectal cancer affects tumor growth and metabolic landscape. JCI Insight. 2021;6.
Scarfe L, Mackie GM, Maslowski KM. Inflammasome-independent functions of NAIPs and NLRs in the intestinal epithelium. Biochem Soc Trans. 2021;49:2601-2610.
2020
Sasaki N, Miyamoto K, Maslowski KM, Ohno H, Kanai T, Sato T. Development of a Scalable Coculture System for Gut Anaerobes and Human Colon Epithelium. Gastroenterology. 2020;159:388-390.e385.
2019
Maslowski KM. Metabolism at the centre of the host-microbe relationship. Clin Exp Immunol. 2019;197:193-204.
2018
Chennupati V, Veiga DF, Maslowski KM, Andina N, Tardivel A, Yu EC, Stilinovic M, Simillion C, Duchosal MA, Quadroni M, Roberts I, Sankaran VG, MacDonald HR, Fasel N, Angelillo-Scherrer A, Schneider P, Hoang T, Allam R. Ribonuclease inhibitor 1 regulates erythropoiesis by controlling GATA1 translation. J Clin Invest. 2018;128:1597-1614.
2015
Allam R, Maillard MH, Tardivel A, Chennupati V, Bega H, Yu CW, Velin D, Schneider P, Maslowski KM. Epithelial NAIPs protect against colonic tumorigenesis. J Exp Med. 2015;212:369-383.
Vieira AT, Macia L, Galvão I, Martins FS, Canesso MC, Amaral FA, Garcia CC, Maslowski KM, De Leon E, Shim D, Nicoli JR, Harper JL, Teixeira MM, Mackay CR. A Role for Gut Microbiota and the Metabolite-Sensing Receptor GPR43 in a Murine Model of Gout. Arthritis Rheumatol. 2015;67:1646-1656.
Sellin ME, Maslowski KM, Maloy KJ, Hardt WD. Inflammasomes of the intestinal epithelium. Trends Immunol. 2015;36:442-450.
2014
Scott C, Bonner J, Min D, Boughton P, Stokes R, Cha KM, Walters SN, Maslowski K, Sierro F, Grey ST, Twigg S, McLennan S, Gunton JE. Reduction of ARNT in myeloid cells causes immune suppression and delayed wound healing. Am J Physiol Cell Physiol. 2014;307:C349-357.
Sellin ME, Müller AA, Felmy B, Dolowschiak T, Diard M, Tardivel A, Maslowski KM, Hardt WD. Epithelium-intrinsic NAIP/NLRC4 inflammasome drives infected enterocyte expulsion to restrict Salmonella replication in the intestinal mucosa. Cell Host Microbe. 2014;16:237-248.
2013
Zaiss MM, Maslowski KM, Mosconi I, Guenat N, Marsland BJ, Harris NL. IL-1β suppresses innate IL-25 and IL-33 production and maintains helminth chronicity. PLoS Pathog. 2013;9:e1003531.
Michallet MC, Rota G, Maslowski K, Guarda G. Innate receptors for adaptive immunity. Curr Opin Microbiol. 2013;16:296-302.
2012
Macia L, Thorburn AN, Binge LC, Marino E, Rogers KE, Maslowski KM, Vieira AT, Kranich J, Mackay CR. Microbial influences on epithelial integrity and immune function as a basis for inflammatory diseases. Immunol Rev. 2012;245:164-176.
2011
Kranich J, Maslowski KM, Mackay CR. Commensal flora and the regulation of inflammatory and autoimmune responses. Semin Immunol. 2011;23:139-145.
Maslowski KM, Mackay CR. Diet, gut microbiota and immune responses. Nat Immunol. 2011;12:5-9.
2009
Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, Artis D, Xavier RJ, Teixeira MM, Mackay CR. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461:1282-1286.